How phase-changing materials can build green structures

How phase-changing materials can build green structures


The statement ‘70 per cent of the buildings India will have by 2030 are yet to be built’ has been repeated so often that it has become a cliché. Still, it underscores the importance of ‘greening’ the construction industry, which has a large carbon footprint. The International Energy Agency has determined that carbon dioxide emissions from existing and new buildings may grow from 194 million tonnes in 2020 to 245 million tonnes by 2040.

Can buildings double as energy storage devices? Yes — with the help of materials that change phases while absorbing or releasing energy. Water becoming vapour or ice is a good example of such ‘phase-changing materials’, or PCMs.

The idea of incorporating PCMs into construction material has been around for some years, driven by climate action imperatives.

PCMs can be embedded into building materials either through macro encapsulation (hollows in slabs, walls or bricks filled with PCMs) or micro encapsulation (PCMs powdered and mixed with construction materials). A recent study by A Aridi of the University of Angers, France, and A Yehya of Harvard University notes that PCMs can save five to 14 times more energy in one unit volume than conventional sensible storage materials (water, masonry, or rock). PCMs can store a considerable amount of thermal energy in a building during off-peak load periods to balance the on-peak demand situation, it says. “Furthermore, latent heat devices are better than sensible because they can store a large amount of heat with only a small to no temperature difference,” the study notes. (Latent heat is the heat energy required for a phase change without changing the temperature.)

Using PCMs in buildings reduces energy consumption and, consequently, carbon dioxide emissions. However, the trade-off is between the cost of the PCM and the emissions produced during its manufacture. The study has delved into the relative merits of different types of PCMs in buildings — and has determined that coconut oil is the best.

The cost factor

PCMs can come from various sources — crude oil (paraffin wax), chemicals (salt hydrates) or plants (palm, soya or coconut oil). The study assessed their relative merits on parameters such as technical appropriateness, economic viability, environmental impact, and social fairness. It looked at each material’s ‘environment cost indicator’ or ECI, and social aspects such as hazards in the mining of metals and minerals.

Four types of PCMs were studied: magnesium nitrate hexahydrate as salt hydrates, octadecane as paraffins, coconut oil, and coconut oil produced with biofertilisers.

In terms of effectiveness, all the candidates showed promise. However, when it came to cost and environmental impact, they varied widely. Octadecane was found costliest, at around $8 a kg, followed by coconut oil ($2 per kg), magnesium nitrate hexahydrate ($0.3 per kg). Octadecane, derived from crude oil, has the highest environmental impact among the four PCMs, but stores and releases the highest amount of energy because of its relatively high latent heat. “This makes it desirable for small spaces,” the study’s authors say.

“The coconut oil PCM using biofertilisers is ecofriendly, non-toxic, transparent, and has excellent chemical and thermo-physical properties for TES [thermal energy storage]. This makes it suitable for various applications. Besides, coconut oil is relatively cheap and is obtainable, renewable, and biodegradable, unlike paraffin, which requires decades to be fully decomposed. Its production positively affects the economy of the agricultural communities that produce it, despite some issues related to cheap and child labour. Consequently, relying on bio-based/plant-based materials is recommended for improving the sustainability of PCM production, keeping in mind the need to enhance the socio-economic conditions of the labour,” says the study.

Waste to PCM

The study notes that there are other bio-based PCMs, too, which may be used in combo, such as beef tallow combined with coconut oil, rapeseed oil, palm kernel oil, palm oil, and soyabean oil, among others. There are PCM materials sourced from waste or by-products such as animal fats, fish wastes, pork lard, beef tallow, chicken fat, plastics and carbon PCM (C-PCM). “New findings and research conducted on these waste products can pave the way for the creation of resilient and inexpensive PCM alternatives in the near future,” the study says.

Published on

August 21, 2022



Source link

Second-hand smoke 10th biggest risk factor for cancer: Lancet study

Second-hand smoke 10th biggest risk factor for cancer: Lancet study


People living in close proximity to those who smoke tobacco may have a higher risk of cancer as a new study published in The Lancet journal has found that second-hand smoking is the tenth biggest risk factor for the disease.

Using results from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2019 study, the researchers investigated how 34 behavioural, metabolic, environmental, and occupational risk factors contributed to deaths and ill health due to 23 cancer types in 2019.

Changes in cancer burden between 2010 and 2019 due to risk factors were also assessed. Estimates of cancer burden were based on mortality and disability-adjusted life-years (DALYs), a measure of years of life lost to death and years lived with disability.

The researchers at the University of Washington, US assumed that all persons living with a daily smoker are exposed to tobacco smoke. They used surveys to estimate the proportion of individuals exposed to secondhand smoke at work.

Top risk factors

The study found that smoking, alcohol use, and high body mass index (BMI), were the top three risk factors for cancer. These were followed by unsafe sex, high fasting blood glucose, particle air pollution, asbestos exposure, diets low in whole grains and milk, and second-hand smoking.

These factors accounted for 3.7 million deaths and 87.8 million DALYs in 2019, the researchers said.

“This study illustrates that the burden of cancer remains an important public health challenge that is growing in magnitude around the world,” said Christopher Murray, Director of the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.

“Smoking continues to be the leading risk factor for cancer globally, with other substantial contributors to cancer burden varying,” said Murray, a co-senior author of the study.

What is second-hand smoking?

Second-hand smoke is smoke from burning tobacco products, like cigarettes, cigars, hookahs, or pipes. Secondhand smoke also is smoke that has been exhaled, or breathed out, by the person smoking.

People may also be exposed to secondhand smoke in public places like bars, restaurants, and casinos, as well as in vehicles.

According to the US Centers for Disease Control and Prevention (CDC), there are more than 7,000 chemicals in tobacco smoke, including hundreds of chemicals that are toxic and about 70 that can cause cancer.

“Secondhand smoke can cause health problems in children and adults, and can even be deadly. Since 1964, about 2,500,000 people who do not smoke have died from health problems caused by secondhand smoke exposure,” the CDC states.

Published on

August 20, 2022



Source link

DCGI approves use of AstraZeneca’s drug for patients with high-risk early breast cancer

DCGI approves use of AstraZeneca’s drug for patients with high-risk early breast cancer


AstraZeneca India, a biopharmaceutical company, on Friday said that it had received the Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer.

The use will be restricted to patients who have previously been treated with neoadjuvant or adjuvant chemotherapy. It is also approved for use in the United States, European Union, Japan, and other countries.

“We are constantly pushing the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. The regulatory approval of Lynparza, the first and only drug targeting BRCA mutations in early breast cancer, reinforces our growing capabilities in innovation and clinical research for providing holistic solutions for cancer treatment in India,” said Gagandeep Singh, Managing Director and Country President, AstraZeneca India.

Meaningful improvement

The approval was based on results from the OlympiA Phase III trial, which suggested that Olaparib demonstrated a statistically significant and clinically meaningful improvement, with an overall survival benefit.

Dr. Anil Kukreja, Vice President, Medical Affairs and Regulatory, AstraZeneca India, said, “The new data from the OlympiA Phase III trial also confirms that it significantly extends the lives of the patients. The approval will provide oncologists with a potential therapeutic option to be given with curative intent to eligible early breast cancer patients.” 

Published on

August 20, 2022



Source link

Bionic hand can be updated with new gestures, anytime, anywhere

Bionic hand can be updated with new gestures, anytime, anywhere


ReutersAustralian swimmer Jessica Smith has had an uneasy relationship with prosthetics since a childhood accident, but her convictions are being challenged by a British bionic hand that can be updated remotely anywhere in the world.

The 2004 Athens Paralympian was born without a left hand.

Her parents were advised to fit a prosthesis to help with her development, but the device caused her to upset a boiling kettle when she was a toddler, causing burns to 15 per cent of her body.

“There’s always been an association between the fact this prosthetic aid didn’t actually help, it created the most traumatic event in my life,” she said.

But her curiosity was sparked when she was approached by COVVI, based in Leeds, northern England, to try its Nexus hand.

Knowing it would be an emotional challenge, Smith was fitted with the device in April at the age of 37. “I think that I was ready to try something like this,” she said.

Bionic hands convert electrical impulses from the muscles in the upper arm into movement powered by motors in the hand, enabling a user to hold a glass, open a door or pick up an egg.

Simon Pollard, who founded COVVI five years ago, said he wanted to add bluetooth to the device to allow the company’s specialists to update it via an app.

“The fact we can change some of the things that the customer wants remotely is a really powerful thing and a first to market,” the chief executive said.

Some rival bionic hands can be app-controlled, but Pollard said the ability to talk to a single device set the Nexus apart.

To do that anonymised data is collected for every user, a task managed by partner NetApp.

Pollard said COVVI had signed up 27 distributors globally, including in Australia, China and the United States, and he aimed to increase monthly production to 100.

Smith, who is a speaker and children’s author, said COVVI was already creating new movements for her.

“I’ve had a few kids ask if I can do different hand gestures, some polite some not so polite,” she said. “I asked COVVI this morning, and I know that will be done in the next couple of hours.”

She said the tech was not just changing her life, it was changing the lives of her three children.

“They think it’s amazing and I’m like half human-half robot,” she said.

She said the “bionic” appearance of the hand was an attraction, given her pride in difference.

“I’m not trying to hide who I am,” she said. “I’m adding and expanding on who I am by being able to access technology that’s never been available before.”

Published on

August 16, 2022



Source link

Zombie crew: How dead spiders returned as robots

Zombie crew: How dead spiders returned as robots


The Spiderman has done a lot of impossible things on the silver screen; now scientists are putting the arachnids that inspired the superhero to funny uses.

Te Faye Yap, a mechanical engineer at Rice University, Houston, noticed that dead spiders always have their legs curled in, and wondered why. She took one up for detailed study and discovered that a spider moves its legs through hydraulic pressure — a chamber in its body pumps air into tubes in its legs, which then stretch out; when air is drawn back, the legs curl in.

Intrigued by this, Yap and her colleague Daniel Preston collected more dead spiders to experiment on.

They stuck a syringe into the spider’s chamber and pushed in air gently — the legs came alive, stretching out. Now you have made yourself a robotic arm that can grip and pick up really tiny objects without damaging them.

The dead spiders can pick up more than 130 per cent of their body weight and last through 1,000 open-close cycles, researchers Yap, Zhen Liu, Anoop Rajappan, Trevor Shimokusu and Preston say in a paper published in Advanced Science. They call the use of biotic materials as robotic components “necrobotics”. Giving the animals a coat of beeswax can slow the loss of body weight. Such “necrobotic grippers” could have multiple applications, including assembling things like microelectronics and for collecting specimens, they say.





Source link

World’s first “synthetic embryo”: why this research is more important than you think

World’s first “synthetic embryo”: why this research is more important than you think


In what’s reported as a world-first achievement, biologists have grown mouse embryo models in the lab without the need for fertilised eggs, embryos, or even a mouse – using only stem cells and a special incubator.

This achievement, published in the journal Cell by a team led by researchers from the Weizmann Institute of Science in Israel, is a very sophisticated model of what happens during early mouse embryo development – in the stage just after implantation.

This is a crucial stage: in humans, many pregnancies are lost around this stage.

Having models provide better understanding to study what can go wrong, and possibly insights into what we may be able to do about it.

The tiniest cluster not only does mimic the cell specification and layout of an early-stage body plan – including precursors of heart, blood, brain and other organs – but also the “support” cells like those found in the placenta and other tissues required to establish and maintain a pregnancy.

The earliest stages of pregnancy are difficult to study in most animals. The embryos are microscopic, tiny clusters of cells, difficult to locate and observe within the uterus.

But we do know that at this stage of development, things can go awry; for example, environmental factors can influence and interfere with development, or cells fail to receive the right signals to fully form the spinal cord, such as in spina bifida. Using models like this, we can start to ask why.

However, even though these models are a powerful research tool, it is important to understand they are not embryos.

They replicate only some aspects of development, but not fully reproduce the cellular architecture and developmental potential of embryos derived after fertilisation of eggs by sperm – so-called natural embryos.

The team behind this work emphasises that they were unable to develop these models beyond eight days, while a normal mouse pregnancy is 20 days long.

Are ‘synthetic embryos’ of humans on the horizon?

The field of embryo modelling is progressing rapidly, with new advances emerging every year.

In 2021, several teams managed to get human pluripotent stem cells (cells that can turn into any other type of cell) to self-aggregate in a Petri dish, mimicking the “blastocyst”.

This is the earliest stage of embryonic development just before the complex process of implantation, when a mass of cells attach to the wall of the uterus.

Researchers using these human embryo models, often called blastoids, have even been able to start to explore implantation in a dish, but this process is much more challenging in humans than it is in mice.

Growing human embryo models of the same complexity that has now been achieved with a mouse model remains a distant proposition, but one we should still consider.

Importantly, we need to be aware of how representative such a model would be; a so-called synthetic embryo in a Petri dish will have its limitations on what it can teach us about human development, and we need to be conscious of that.

An important consideration is whether using cells for this particular type of research – trying to mimic an embryo in a dish – requires any specific consent.

However, it is important to recognise that there are existing laws and international stem cell research guidelines that provide a framework to regulate this area of research.

In Australia, research involving human stem cell embryo models would require licensing, similar to that required for the use of natural human embryos under law that has been in place since 2002.

However, unlike other jurisdictions, Australian law also dictates how long researchers can grow human embryo models, a restriction that some researchers would like to see changed.

There is a distinction between banning the use of this technology and technologies like cloning in humans for reproductive use, and allowing research using embryo models to advance our understanding of human development and developmental disorders that we can’t answer by any other means.

The science is rapidly advancing. While mostly in mice at this stage, now is the time to discuss what this means for humans, and consider where and how we draw the line in the sand as the science evolves.

By Megan Munsie, Professor Emerging Technologies (Stem Cells), The University of Melbourne

Published on

August 07, 2022



Source link

YouTube
Instagram
WhatsApp